Protagonist Therapeutics, Inc. (PTGX) Stock Score, Valuation & Financial Research
Protagonist Therapeutics, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for PTGX
Protagonist Therapeutics, Inc. currently has a Wall Street Score of 27/100. The stored market price is $143.4. Its financial score is 36/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Protagonist Therapeutics, Inc. does
Protagonist Therapeutics, Inc. is a biopharmaceutical firm dedicated to discovering and advancing peptide-based therapies. Their research primarily focuses on treatments for hematological and blood conditions, as well as inflammatory and immune-mediated disorders. The company's pipeline features rusfertide (PTG-300), an injectable hepcidin mimetic currently undergoing Phase II clinical trials for the management of polycythemia vera, hereditary hemochromatosis, and other blood-related ailments. Also in Phase II development is PN-943, an oral peptide engineered as a specific antagonist of alpha-4-beta-7 integrin, intended for addressing inflammatory bowel disease (IBD). Furthermore, they are progressing PN-235, an orally administered antagonist specifically targeting the interleukin-23 receptor, designed for both IBD and various non-IBD therapeutic applications. Protagonist Therapeutics ma
PTGX financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $143.4
- Market capitalization:
- $9.22B
- Revenue:
- $74.1M
- Net income:
- $-114.7M
- Free cash flow:
- $56.1M
- Cash:
- $193.7M
- Total debt:
- $9.8M
- EPS:
- -2.05
- Financial score:
- 36/100
- Valuation score:
- 0/100
- Revenue score:
- 20/100
What stands out
- Reported year-over-year revenue growth is +0.6%.
- Free cash flow is $56.1M, showing positive cash generation.
- The balance sheet shows $193.7M of cash versus $9.8M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 36/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research PTGX
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.